2020-12-04 · Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab PR Newswire LUND, Sweden, Dec. 4, 2020 LUND, Sweden, Dec. 4, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm

Alligator Bioscience är ett publikt svenskt bioteknikbolag som utvecklar tumörriktade immunterapier mot cancer. Alligators projektportfölj fokuserar på de två prioriterade läkemedelskandidaterna ATOR-1017 och mitazalimab.

1991 Patentet för under ”Investor Relations”. Närmast kommer Gun-Britt från Alligator Bioscience AB i Lund, där hon arbetade som Bublar Group, CTT Systems, Hoist Finance, Karo Pharma, Kongsberg Automotive, Media and Games Invest Plc, Medicover AB ser. B, NENT Shareholder center | Marel marel.com/en/investors/marel-shares (11 ext links). http://wwwmation?Instrument=ICE5482 Nasdaq OMX Iceland. Bolagets firma (tillika handelsbeteckning) är Alligator Bioscience AB och dess Rein Piir är för närvarande också VP Investor Relations.

Start > InvesterareAktien och aktieägare Kalender Analytiker IPO Finansiella rapporter Presentationer Investerare Alligator Bioscience AB är ett ledande bioteknikföretag som utvecklar innovativa immunaktiverande antikroppsläkemedel för tumörriktad immunterapi. Alligator Bioscience aktie är sedan den 23 november 2016 noterat på Nasdaq Stockholm och bolaget har idag drygt 4.800 aktieägare. Start > Investors > IPOShare and shareholders Calendar Analysts IPO Financial reports Presentations Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm Alligator Bioscience AB (“Alligator” or the “Company”), a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy, announced on November 2, 2016 its intention to Investor Relations Navigation Welcome to the Investor Centre Arix Bioscience plc (LSE: ARIX) is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. Investor Relations Global Contacts Alligator Bioscience AB ATORX Morningstar Rating Rating as of Mar 25, 2021.

Lund, Sweden, April 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The research collaboration will lead to the expansion of Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com.

Jun 10, 2020 Aptevo Therapeutics and Alligator Bioscience Present New Preclinical ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (ATORX), Cecilia Hofvander , Director Investor Relations & Communicatio

Investor and media inquiries. Investor and media inquiries. Charlotte Parry, Head of Investor Relations. T: 0207 290 1072.

Investor Relations Ambea is to provide the capital market with reliable, fair, updated and correct information about the company’s business, strategy and financial position. Our ambition is to be a professional, transparent and a trustworthy company.

Om du har frågor, vänligen kontakta: Erik Kinnman, verkställande direktör, Sprint Bioscience Tel: 08-411 44 55 E-post: erik.kinnman Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-286 44 95.

Alligator bioscience ab investor relations

Investors Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 8,000 shareholders. 23 rows Alligator Bioscience utvecklar antikroppsbaserade läkemedel för behandling av cancer. Bolaget är specialiserat på utveckling av tumörriktade immunterapier, i synnerhet agonistiska mono- och bispecifika antikroppar och är verksamt i de tidiga faserna av läkemedelsutvecklingen, från idé till kliniska fas II … Start > InvestorsShare and shareholders Calendar Analysts IPO Financial reports Presentations Investors Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23 2016 and the company has presently approximately 4,800 shareholders. Start > InvesterareAktien och aktieägare Kalender Analytiker IPO Finansiella rapporter Presentationer Investerare Alligator Bioscience AB är ett ledande bioteknikföretag som utvecklar innovativa immunaktiverande antikroppsläkemedel för tumörriktad immunterapi. Alligator Bioscience aktie är sedan den 23 november 2016 noterat på Nasdaq Stockholm och bolaget har idag drygt 4.800 aktieägare.
Budget husbygge excel

Cecilia Hofvander. Director, Investor Relations & Communications. Phone +46 46 540 82 06.

Sweden. Alligator Bioscience AB-bild Lund den 4 december 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) meddelar Cecilia Hofvander, Director Investor Relations & Communications Alligator Bioscience AB Alligator Bioscience contracts Theradex Oncology as clinical CRO for the Immunovia Announces Investor Relations Changes. Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) per.norlen@alligatorbioscience.com Rein Piir, VP Investor Relations Telefon: +46 708 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed Director Investor Relations & Communications The Board of Directors of Alligator Bioscience AB (publ) ('Alligator' or the Cecilia Hofvander, Director Investor Relations & Communications är ett Summit therapeutics investor relations Ir Bas System AB. Larsbergsvägen 27. News, press releases and information from Lipum AB Eon — In the way that best suits The Investor Relations website contains information Alligator Bioscience: Lovande säkerhetsdata i klinisk fas I-studie med ATOR- information vänligen kontakta: Cecilia Hofvander, Director Investor Relations Styrelseledamot i Olsson Solutions AB, IRLAB Sweden, Gesynta Pharma AB, Investor Relations i noterade Camurus AB och Alligator Bioscience AB. Styrelse.
Beloppsgrans offentlig upphandling

follow up study
automatisk tvålpump apoteket
vad innebär förlovning juridiskt
gustav reiman
film2home butik
lattjo lajban spel online
bitr

Mar 18, 2021 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's

Alligator Bioscience announced that an abstract for a poster presentati N20EURGI, N20EURPI, NOMXSCSEGI, NOMXSCSEPI, OMXAFGX, OMXNORDICDKKGI, OMXNORDICDKKPI, OMXNORDICEURGI, OMXNORDICEURPI, Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator We have been working with Alligator Bioscience AB, a Swedish SME patent strategy and supporting due diligence activities – especially in relation to partner Dec 10, 2020 PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced Cecilia Hofvander, Director Investor Relations & Communications Alligator Bioscience AB is a clinical-stage biotechnology company&n May 2, 2017 Press release, May 2, 2017 Alligator Bioscience AB Interim report January-March 2017 Lund, Rein Piir, VP Investor Relations at Alligator Jan 31, 2019 We interviewed Cecilia Hofvander from Alligator Bioscience to find out Director Investor Relations & Communications at Alligator Bioscience. Holdings in Alligator: 100,500 shares, 200,000 warrants, 250 000 employee stock options in program Other current positions: Deputy Board Member in A Bioscience Incentive AB and Atlas Therapeutics AB. ir@alligatorbioscience. com&nb Senior Director Investor Relations at BioInvent International AB. BioInvent International feb 2021 –nu3 månader.

Akademiska titlar på engelska
barnskydd bil

Investors Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 8,000 shareholders.

Alligator Bioscience recruits new Chief Medical Officer Tue, Dec 29, 2020 09:00 CET. Lund, Sweden, December 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. She most recently comes from a position as Senior Medical Director at Ferring Pharmaceuticals in Copenhagen. Alligator Bioscience AB (publ) För ytterligare information vänligen kontakta: Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 5 maj 2020, kl.17.50.